Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
17.23
-0.01 (-0.06%)
Sep 18, 2024, 4:00 PM EDT - Market closed

Company Description

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States.

The company’s lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors.

Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.

In addition, the company’s development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma.

It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib.

Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024.

Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Cullinan Therapeutics, Inc.
Cullinan Therapeutics logo
Country United States
Founded 2016
IPO Date Jan 8, 2021
Industry Biotechnology
Sector Healthcare
Employees 85
CEO Nadim Ahmed

Contact Details

Address:
One Main Street, Suite 1350
Cambridge, Massachusetts 02142
United States
Phone 617 410 4650
Website cullinantherapeutics.com

Stock Details

Ticker Symbol CGEM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $21.00
CIK Code 0001789972
CUSIP Number 230031106
ISIN Number US2300311063
Employer ID 81-3867811
SIC Code 2836

Key Executives

Name Position
Nadim Ahmed Chief Executive Officer
Mary Fenton Chief Financial Officer

Latest SEC Filings

Date Type Title
Sep 17, 2024 8-K Current Report
Sep 5, 2024 144 Filing
Aug 8, 2024 10-Q Quarterly Report
Aug 8, 2024 8-K Current Report
Jul 5, 2024 144 Filing
Jun 27, 2024 8-K Current Report
Jun 7, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jun 4, 2024 EFFECT Notice of Effectiveness
Jun 4, 2024 424B3 Prospectus
Jun 3, 2024 8-K Current Report